News Gedeon Richter OTC Markets

Stocks

GEDSF

US3684672054

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 15:12:15 2025-07-28 EDT			5-day change	1st Jan Change
30.92 ^USD	+24.45%		-.--%	-

06-29	Gedeon Richter plc announces Resignation of Péter Cserháti as Member of the Board of Directors, with Effect from 1 July 2026	CI
06-16	AI in Hungary could unlock productivity gains of EUR15 billion, McKinsey says	RE

All News

Mentions Relevance

06-29	Gedeon Richter plc announces Resignation of Péter Cserháti as Member of the Board of Directors, with Effect from 1 July 2026	CI
06-10	Gedeon Richter : Richter and Hetero Announce Global Cooperation for the Development and Commercialization of Semaglutide Injection (Generic of Ozempic®)	PU
06-10	Gedeon Richter Plc. and Hetero Labs Ltd. Announce Global Collaboration Agreement for Joint Development, Registration, and Commercialization of Semaglutide Injection	CI
05-29	Gedeon Richter PLC Approves Dividend for the Financial Year 2025	CI
05-27	Hungary's Richter and Acrux agree to license transdermal estradiol spray for Australia	RE
05-27	Gedeon Richter : Richter and Acrux agree to license Lenzetto® for Australia	PU
05-15	Gedeon Richter PLC, Q1 2026 Earnings Call, May 12, 2026
05-14	Gedeon Richter : Transactions with Treasury Shares	PU
05-12	Gedeon Richter PLC Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-12	Gedeon Richter : Extraordinary Information	PU
05-12	Hungary's Richter says 2026 guidance fully reiterated high-single-digit growth in revenues and clean EBIT (at constant exchange rates)	RE
05-12	Gedeon Richter : Interim management statement	PU
05-12	Gedeon Richter : RichterIRpresentation May 2026	PU
05-12	Gedeon Richter : PresentationQ12026	PU
05-12	Gedeon Richter : Richter publishes Q1 2026 results	PU
05-12	Gedeon Richter : Earnings presentation Q1 2026 (PresentationQ12026)	PU
05-12	Gedeon Richter : Investor presentation Q1 2026 (RichterIRpresentation May 2026)	PU
05-11	Gedeon Richter Seeks Acquisitions	CI
04-29	Gedeon Richter : Corporate Governance Report from 2025	PU
04-29	Gedeon Richter : AGM Resolutions	PU
04-29	Gedeon Richter : Remuneration Report	PU
04-29	Gedeon Richter : CG Declaration	PU
04-29	Gedeon Richter : GM - Resolutions	PU
04-29	Gedeon Richter : Update on Phase II study of ABBV-932 (RGH-932) for the treatment of bipolar depression	PU
04-29	Gedeon Richter Provides Update On Phase II Clinical Trial Of ABBV-932 (RGH-932) For Bipolar Depression	CI